|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane显示文摘 | Buzdar AU Robertson JF Eiermann W | 2002 | Cancer2002，95，9： | 1 |
| 2 | Phase m study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial显示文摘 | Eiermann W Pienkowski T Crown J | 2011 | J Clin Oncol2011，29，： | 1 |
| 3 | Neoadjuvantand adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with aparallel HER2-negative cohort显示文摘 | Gianni L Eiermann W Semiglazov V eral | 2014 | Lancet Oncol2014，15，6： | 1 |
| 4 | Neoadjuvant and adjuvant trastuzumab in patients with HER-2-positive locally ad- vanced breast cancer (NOAH) : follow-up of a randomised con- trolled superiority trial with a parallel HER-2-negative cohort显示文摘 | Gianni L Eiermann W Semiglazov V | 2014 | Lancet Oncol2014，15，6： | 1 |
| 5 | Phase Ⅲ randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetax- el and trastuzumab (AC→TH) with docetaxel, carboplatin and trastu- zumab(TCH) in HER2 positive early breast cancer patients: BCIRG 006 study显示文摘 | Slamon D Eiermann W Robert N | 2006 | Breast Cancer Res Treat2006，100，1： | 1 |
| 6 | Preoperative treatment of postmenopausal breast cancer patients with letro- zole: a randomized double-blind muhicenter study显示文摘 | Eiermann W Paepke S Appfelstaedt J | 2001 | Ann Oncol2001，12，11： | 1 |
| 7 | Adjuvant trastuzumab in HER2-positive breast cancer 显示文摘 | Simon D Eiermann W Robert N | 2011 | N EngI J Med2011，365，14： | 1 |
| 8 | Preoperative treatment of postmenopausal breast cancer patients with letrozole : a randomized double- blind multicenter study 显示文摘 | Eiermann W Paepke S Appfelstaedt L | 2001 | Ann Oncol2001，12，11： | 1 |
| 9 | Adjuvant trastuzumab in HER2-Positive breast cancer显示文摘 | Slamon D Eiermann W Robert N | 2011 | N Engl J Med2011，365，14： | 1 |
| 10 | A phase Ⅲ randomized trial comparing docetaxel in combination with doxorubiein and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (ACT) in women with Her 2/neu negative axillary lymph node positive early breast cancer显示文摘 | Eiermann W Pienkowski T Crown J | 2009 | Cancer Res2009，77，： | 1 |
| 11 | Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer 显示文摘 | GIANNI L BASELGA J EIERMANN W | 2009 | J Clin Oneol2009，27，15： | 1 |
| 12 | Adjuvant trastuzumab in HER-2-posidve breast cancer显示文摘 | Slamon D Eiermann W Robert N | 2011 | N Engl J Med2011，365，14： | 1 |
| 13 | Acceleration of relaxation methods for non-Hermitian linear systems 显示文摘 | Eiermann M Niethammer W Varga R S | 1992 | Siam J Matrix Anal1992，13，3： | 1 |
| 14 | BCIRG 005 main efficacy analysis: a phase Ⅲ randomized trial comparing do cetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubiein and eyelophosphamlde followed by docetaxel (ACT) in women with Her-2/neu negative axillary lymph node positive early breast cancer 显示文摘 | Eiermann W Pienkowski T Crown J | 2009 | Cancer Res2009，6977，： | 1 |
| 15 | Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone,in patients with HER2-positive locally advanced breast cancer(the NOAH trial):a randomised controlled superiority trial with a parallel HER2-negative cohort显示文摘 | Gianni L Eiermann W Semiglazov V | 2010 | Lancet2010，375，9712： | 1 |
| 16 | Adjuvant trastuzumab in HER2-positive breast cancer显示文摘 | Slamon D Eiermann W Robert N | 2011 | N Engl J Med2011，365，14： | 1 |
| 17 | Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone,in patients with HER2-positive locally advanced breast cancer (the NOAH trial):a randomised controlled superiority trial with a parallel HER2-显示文摘 | Gianni L Eiermann W Semiglazov V | | 0，，9712： | 1 |
| 18 | Adjuvant trastuzumab in Her-2 positive breast cancer显示文摘 | Slamon D Eiermann W Robert N | 2011 | N Engl J Med2011，365，14： | 1 |
| 19 | Phase Ⅲ randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC/T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC/ETH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study显示文摘 | SLAMON D EIERMANN W ROBERT N | 2005 | Breast Cancer Res Treat2005，94，1： | 1 |
| 20 | An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane显示文摘 | Buzdar AU Robertson JF Eiermann W etal | 2002 | Cancer2002，，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员